Buy tesofensine online NS-2330

SCIENTIFIC RESEARCH | NEUROPHARMACOLOGY

Buy tesofensine online(NS-2330): Mechanism of Action and Scientific Research

Explore Tesofensine, a triple monoamine reuptake inhibitor studied in neuropharmacology and metabolic research. Learn about its mechanism of action, scientific applications, molecular properties and product specifications.

Scientific Overview

Tesofensine, also known as NS-2330, inhibits the reuptake of dopamine, norepinephrine and serotonin. These neurotransmitter systems are involved in central nervous system signaling, appetite regulation and other physiological processes.

1. What Is Tesofensine?

Tesofensine is a small-molecule research compound investigated for its effects on monoamine neurotransmitter transporters. Initially explored in clinical research involving neurodegenerative disorders, it later attracted interest in studies examining appetite regulation, energy metabolism and body-weight changes.

Its pharmacological profile distinguishes it from compounds that selectively target a single monoamine transporter. Tesofensine acts on three major transporters in the central nervous system.

2. Tesofensine Mechanism of Action

Tesofensine acts as a triple monoamine reuptake inhibitor (TRI). It inhibits the transporters responsible for removing dopamine, norepinephrine and serotonin from the synaptic space, thereby modulating monoaminergic neurotransmission.

Dopamine Transporter (DAT)

DAT inhibition reduces dopamine reuptake and influences dopaminergic signaling associated with motivation, reward and feeding behavior.

Norepinephrine Transporter (NET)

NET inhibition reduces norepinephrine reuptake and modulates noradrenergic signaling involved in arousal and autonomic processes.

Serotonin Transporter (SERT)

SERT inhibition reduces serotonin reuptake, influencing serotonergic signaling involved in mood, appetite and other physiological functions.

Research using experimental models has demonstrated inhibitory activity at all three monoamine uptake sites. PET studies have also investigated dopamine transporter occupancy associated with Tesofensine.

Reference: Tesofensine and dopamine transporter occupancy measured by PET. European Neuropsychopharmacology (2014).

3. Scientific Research Applications

Neuropharmacology Research

Tesofensine has been investigated as a research compound for studying monoaminergic neurotransmission. Its combined activity on DAT, NET and SERT provides a model for exploring how transporter inhibition influences central nervous system signaling.

Appetite and Energy Metabolism

Researchers have examined the relationship between Tesofensine, appetite regulation and energy expenditure. A 2010 study investigated its effects on energy metabolism and appetite in overweight and moderately obese men.

Reference: Sjödin et al. (2010). The effect of Tesofensine on energy metabolism and appetite. International Journal of Obesity.

Hypothalamic Neuron Research

A 2024 preclinical study investigated Tesofensine's effects on GABAergic neurons in the lateral hypothalamus. Researchers reported changes in neuronal activity and food intake in experimental models, providing further insight into potential neural mechanisms.

Reference: Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons. PLOS ONE (2024).

4. Clinical Research Findings

A randomized, double-blind, placebo-controlled Phase II trial published in The Lancet in 2008 investigated Tesofensine in 203 adults with obesity over 24 weeks.

The study reported dose-dependent body-weight reductions in the Tesofensine groups. Changes in heart rate and other adverse events were also observed, highlighting the importance of safety and tolerability evaluation.

Reference: Astrup et al. (2008). Effect of Tesofensine on bodyweight loss, body composition, and quality of life in obese patients. The Lancet.

Research Note

Clinical trial findings do not establish regulatory approval or suitability for human use. Tesofensine is presented here as an investigational research compound.

5. Tesofensine Product Specifications

The following product details are provided for research identification and laboratory reference.

Product Name: Tesofensine

Product Type: Inhibitor

Synonyms: NS 2330, NS-2330, NS2330

Purity: 98%

Molecular Formula: C17H23Cl2NO

Molecular Weight: 328.28 g/mol

Solubility: Less than 1 mg/mL; described as slightly soluble or insoluble in the supplied product information.

Molecular Structure Information

SMILES:

[H][C@]12CC[C@]([H])([C@H](COCC)[C@H](C1)c1ccc(Cl)c(Cl)c1)N2C

6. Preparation, Storage and Handling

Powder Storage: Supplier-listed condition: -2°C for 3 years. Confirm the intended temperature with the supplier.

In-Solvent Storage: -80°C for 2 years, according to the supplied product information.

Vial Handling: Small amounts of product may occasionally become trapped in the vial seal during shipment or storage. If necessary, briefly centrifuge the vial using a tabletop centrifuge to bring the material down from the cap.

Shipping: Certain products may require shipment on dry ice. Additional dry ice fees may apply.

Storage durations are supplier-provided specifications and should be confirmed against the product's Certificate of Analysis (CoA) and handling documentation.

7. Frequently Asked Questions

What is Tesofensine also known as?

Tesofensine is also known as NS-2330, NS 2330 and NS2330.

How does Tesofensine work?

It inhibits dopamine, norepinephrine and serotonin reuptake through DAT, NET and SERT transporter inhibition.

What is the molecular weight of Tesofensine?

The supplied molecular weight is 328.28 g/mol.

What are the research applications of Tesofensine?

Research has investigated its monoamine transporter activity, neuropharmacological effects, appetite regulation and energy metabolism.

How should Tesofensine be stored?

Follow the supplier's product-specific storage instructions. Confirm the listed powder storage temperature before use.

8. Scientific References

  1. Astrup A, et al. (2008). Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients. The Lancet, 372, 1906–1913. PubMed
  2. Astrup A, et al. (2008). Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Obesity. PubMed
  3. Sjödin A, et al. (2010). The effect of tesofensine on energy metabolism and appetite. International Journal of Obesity. Article
  4. Tesofensine and dopamine transporter occupancy measured by PET. (2014). European Neuropsychopharmacology. DOI
  5. Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons. (2024). PLOS ONE. Full Text

Explore Scientific Research Products

Discover research compounds and laboratory products for scientific applications.

SEARCH PRODUCTS

Disclaimer: This article is for scientific and educational purposes only. Tesofensine is presented as an investigational research compound and is not intended for human or veterinary use. Consult applicable safety documentation and regulations before handling.

22nd Sep 2026

Recent Posts